News | January 06, 2026
PathoCare Holdings valued at $1.75 billion following major third-party tender offer
The company previously completed a $150 million venture investment, acquisition, and recapitalization
The company previously completed a $150 million venture investment, acquisition, and recapitalization
Renalyx will continue operating as an independent unit within the group
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
The Dengue IgG/IgM Rapid Test is a diagnostic tool used to detect antibodies against the dengue virus in blood samples
Achira is engaged in development and commercialization of PoC medical test kits in India
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
It plans launch various other health monitoring tools for smartphones, making existing devices obsolete
TAH is now undergoing regulatory clearance and final quality control procedures for the swab deployment in India, EU, Singapore, UK, US, Australia and others for COVID-19 testing
Subscribe To Our Newsletter & Stay Updated
